参考文献:1.Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.PubMedCentral CrossRef PubMed 2.Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol. 2012;30(23):2912–8.CrossRef PubMed 3.Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242(3):302–11; discussion 311–3.PubMedCentral PubMed 4.Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998;16(6):2253–60.PubMed 5.Carlson GW, Page AJ, Cohen C, et al. Regional recurrence after negative sentinel lymph node biopsy for melanoma. Ann Surg. 2008;248(3):378–86.PubMed 6.Zogakis TG, Essner R, Wang HJ, et al. Melanoma recurrence patterns after negative sentinel lymphadenectomy. Arch Surg. 2005;140(9):865–71; discussion 871–2.CrossRef PubMed 7.Chao C, Wong SL, Edwards MJ, et al. Sentinel lymph node biopsy for head and neck melanomas. Ann Surg Oncol. 2003;10(1):21–6.CrossRef PubMed 8.Scoggins CR, Martin RC, Ross MI, et al. Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol. 2010;17(3):709–17.CrossRef PubMed 9.Yee VS, Thompson JF, McKinnon JG, et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol. 2005;12(6):429–39.CrossRef PubMed 10.Li LX, Scolyer RA, Ka VS, et al. Pathologic review of negative sentinel lymph nodes in melanoma patients with regional recurrence: a clinicopathologic study of 1152 patients undergoing sentinel lymph node biopsy. Am J Surg Pathol. 2003;27(9):1197–202.CrossRef PubMed 11.McDonald K, Page AJ, Jordan SW, et al. Analysis of regional recurrence after negative sentinel lymph node biopsy for head and neck melanoma. Head Neck. 2013;35(5):667–71.CrossRef PubMed 12.Karim RZ, Scolyer RA, Li W, et al. False negative sentinel lymph node biopsies in melanoma may result from deficiencies in nuclear medicine, surgery, or pathology. Ann Surg. 2008;247(6):1003–10.CrossRef PubMed 13.Caraco C, Marone U, Celentano E, Botti G, Mozzillo N. Impact of false-negative sentinel lymph node biopsy on survival in patients with cutaneous melanoma. Ann Surg Oncol. 2007;14(9):2662–7.CrossRef PubMed 14.Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. Ann Surg Oncol. 2006;13(12):1655–63.CrossRef PubMed 15.Jones EL, Jones TS, Pearlman NW, et al. Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. JAMA Surg. 2013;148(5):456–61.CrossRef PubMed 16.Morton DL CL, Wong J. Intraoperative lymphatic mapping and selective lymphadenectomy: technical details of a new procedure for clinical stage I melanoma. In Paper presented at: 42nd Annual Meeting of the Society of Surgical Oncology, May 20–22, 1990, Washington, DC. 17.Essner R FL, Morton DL. A useful adjunct to intraoperative lymphatic mapping and selective lymphadenectomy in patients with clinical stage I melanoma. In Paper presented at: Annual Meeting of the Society of Surgical Oncology, March 17–20, 1994, Houston. 18.Bagaria SP, Faries MB, Morton DL. Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute. J Surg Oncol. 2010;101(8):669–76.PubMedCentral CrossRef PubMed 19.Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg. 1999;230(4):453–63; discussion 463–5.PubMedCentral CrossRef PubMed 20.Dessureault S, Soong SJ, Ross MI, et al. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol. 2001;8(10):766–70.CrossRef PubMed 21.Yao KA, Hsueh EC, Essner R, Foshag LJ, Wanek LA, Morton DL. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Ann Surg. 2003;238(5):743–7.PubMedCentral CrossRef PubMed 22.Lin D, Franc BL, Kashani-Sabet M, Singer MI. Lymphatic drainage patterns of head and neck cutaneous melanoma observed on lymphoscintigraphy and sentinel lymph node biopsy. Head Neck. 2006;28(3):249–55.CrossRef PubMed 23.Fincher TR, O’Brien JC, McCarty TM, et al. Patterns of drainage and recurrence following sentinel lymph node biopsy for cutaneous melanoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2004;130(7):844–8.CrossRef PubMed 24.Veenstra HJ, Klop WM, Speijers MJ, et al. Lymphatic drainage patterns from melanomas on the shoulder or upper trunk to cervical lymph nodes and implications for the extent of neck dissection. Ann Surg Oncol. 2012;19(12):3906–12.PubMedCentral CrossRef PubMed 25.Joosse A, Collette S, Suciu S, et al. Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials. J Clin Oncol. 2013;31(18):2337–46.CrossRef PubMed 26.Joosse A, de Vries E, Eckel R, et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Investig Dermatol. 2011;131(3):719–26.CrossRef PubMed 27.Scoggins CR, Ross MI, Reintgen DS, et al. Gender-related differences in outcome for melanoma patients. Ann Surg. 2006;243(5):693–8; discussion 698–700.PubMedCentral CrossRef PubMed 28.Balch CM, Murad TM, Soong SJ, Ingalls AL, Richards PC, Maddox WA. Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer. 1979;43(3):883–8.CrossRef PubMed
作者单位:David Y. Lee MD (1) Kelly T. Huynh MD (1) Annabelle Teng MD (2) Briana J. Lau MD (1) Sarah Vitug BS (3) Ji-Hey Lee PhD (4) Stacey L. Stern MS (4) Leland J. Foshag MD (1) Mark B. Faries MD (1)
1. Department of Surgical Oncology, The John Wayne Cancer Institute at Providence St. John’s Health Center, Santa Monica, CA, USA 2. Department of Surgery, Mount Sinai, St-Luke’s-Roosevelt Hospital Center, New York, NY, USA 3. Ochsner Clinical School, University of Queensland School of Medicine, Saint Lucia, QLD, Australia 4. Department of Biostatistics, The John Wayne Cancer Institute at Providence St. John’s Health Center, Santa Monica, CA, USA
刊物主题:Surgical Oncology; Oncology; Surgery;
出版者:Springer US
ISSN:1534-4681
文摘
Background The status of the sentinel lymph node in melanoma is an important prognostic factor. The clinical predictors and implications of false-negative (FN) biopsy remain debatable.